<figure><img src="https://assets.bwbx.io/images/users/iqjWHBFdfxIU/iMZvD5K_O_eI/v5/-1x-1.jpg"><figcaption><div><p>Source: Bloomberg, 0:00</p></div><div></div></figcaption></figure><p>Joel Lewis, CEO at Galectin Therapeutics (NASDAQ: GALT), joins to discuss his firm, medical trials, and the market potential for their current drug development. Hosted by Paul Sweeney and Matt Miller.</p>

Joel Lewis, CEO at Galectin Therapeutics (NASDAQ: GALT), joins to discuss his firm, medical trials, and the market potential for their current drug development. Hosted by Paul Sweeney and Matt Miller.

Biotech and Drug Development

Alix Steel and Paul Sweeney harness the power of Bloomberg Intelligence to analyze market news and provide in-depth company and industry research.

Bloomberg Intelligence

hero

Matt Miller and Paul Sweeney focus on market coverage as Wall Street begins its day, with analysis from Bloomberg Opinion writers, Bloomberg Intelligence analysts, and influential newsmakers.